Effect of genetic variations on ticagrelor plasma levels and clinical outcomes
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes
Authors
Keywords
-
Journal
EUROPEAN HEART JOURNAL
Volume 36, Issue 29, Pages 1901-1912
Publisher
Oxford University Press (OUP)
Online
2015-05-03
DOI
10.1093/eurheartj/ehv116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile of the Oral Antiplatelet Agent Ticagrelor
- (2012) Renli Teng CLINICAL PHARMACOKINETICS
- Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
- (2011) L. B. Ramsey et al. GENOME RESEARCH
- ProbABEL package for genome-wide association analysis of imputed data
- (2010) Yurii S Aulchenko et al. BMC BIOINFORMATICS
- In Vitro Evaluation of Potential Drug-Drug Interactions with Ticagrelor: Cytochrome P450 Reaction Phenotyping, Inhibition, Induction, and Differential Kinetics
- (2010) D. Zhou et al. DRUG METABOLISM AND DISPOSITION
- Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects
- (2010) R. Teng et al. DRUG METABOLISM AND DISPOSITION
- Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
- (2010) Renli Teng et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI
- (2010) Jessica L. Mega et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry
- (2010) Henrik Sillén et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis
- (2010) Jessica L Mega et al. LANCET
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
- (2010) Lars Wallentin et al. LANCET
- Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
- (2009) Stefan James et al. AMERICAN HEART JOURNAL
- Ticagrelor: The First Reversibly Binding Oral P2Y12Receptor Antagonist
- (2009) Steen Husted et al. Cardiovascular Therapeutics
- Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
- (2009) C. Varenhorst et al. EUROPEAN HEART JOURNAL
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects
- (2009) Deepak Voora et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ticagrelor binds to human P2Y12independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation
- (2009) J. J. J. VAN GIEZEN et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
- (2009) Lars Wallentin et al. NEW ENGLAND JOURNAL OF MEDICINE
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now